The ALS Association recently announced that three new grants are being awarded to address unmet needs regarding the clinical management of amyotrophic lateral sclerosis (ALS). These funds will support research to benefit both ALS patients and caregivers by reducing unwanted weight loss in these patients, advancing techniques to improve their…
News
BrainStorm Cell Therapeutics Inc. will be holding a conference call and webcast session to discuss data regarding the company’s phase 2a clinical trial of NurOwn™ for amyotrophic lateral sclerosis (ALS). BrainStorm is a leading biotechnology company in the ALS space that is developing adult stem cell technologies to address neurodegenerative…
News
Israel’s OCS Awards $1.1 Million To BrainStorm Cell Therapeutics For Amyotrophic Lateral Sclerosis
BrainStorm Cell Therapeutics Inc. received nearly $1.1 million in funding from Israel’s Office of the Chief Scientist (OCS) to support the development of NurOwn™, BrainStorm’s therapeutic platform for treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). BrainStorm is a biotechnology company dedicated to the development of innovative adult…
The ALS Association announced that $326,662 will be used to fund new Amyotrophic Lateral Sclerosis (ALS) research. The new funding will seek to expand ongoing research projects to increase the knowledge of the most frequent genetic cause of the disease and support clinical trials dedicated to those that carry…
Yumanity Therapeutics, a new biotechnology company working on the development of drug discoveries for the treatment of conditions caused by protein misfolding, was launched last Monday by well-known leader in the biotech industry Tony Coles, M.D., who is not only the founding investor of the company, but will also serve as its chairman and chief…
A new study entitled “Aggregation propensities of Superoxide Dismutase G93 hotspot mutants mirror Amyotrophic Lateral Sclerosis clinical phenotypes” identified a mechanism that leads to the aggregation of SOD protein mutant forms that are typically found in Amyotrophic lateral sclerosis (ALS) motor neurons. The study opens new therapeutic avenues…
New research at Washington University School of Medicine in St. Louis and Cedars-Sinai Medical Center in Los Angeles indicates that genetic mutations may underlie more amyotrophic lateral sclerosis (ALS) than scientists had previously realized. The research results also revealed that the quantity of mutated genes influences at what age…
According to a July 2014 report in the Morbidity and Mortality Weekly Report (MMWR), amytrophic lateral sclerosis (ALS) or Lou Gehrig’s disease is estimated to affect about 3.9 individuals for every 100,000 Americans, most commonly diagnosed in the elderly who are in their 70s. While the cause…
Recent Posts
- Specialized ALS care linked to longer survival in real-world study
- New AI model shows promise for spotting genetic ALS risk, study says
- Electrical spinal stimulation reduces toxic protein clumps in ALS mice
- Coya 302: A New Approach to Neurodegeneration
- Experimental treatment shows promise in patient with rare genetic form of ALS